No headlines found.
Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now
Globe Newswire (Wed, 12-Jun 7:00 AM ET)
Presenting on the Emerging Growth Conference 72 Day 1 on June 12 Register Now
Globe Newswire (Tue, 11-Jun 7:00 AM ET)
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.
Inmed Pharmaceuticals - Common Shares trades on the NASDAQ stock market under the symbol INM.
As of September 9, 2024, INM stock price declined to $0.26 with 175,943 million shares trading.
INM has a beta of 2.31, meaning it tends to be more sensitive to market movements. INM has a correlation of 0.04 to the broad based SPY ETF.
INM has a market cap of $2.33 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, INM stock traded as high as $59.25 and as low as $.12.
The top ETF exchange traded funds that INM belongs to (by Net Assets): YOLO.
INM has underperformed the market in the last year with a price return of -69.6% while the SPY ETF gained +24.2%. However, in the short term, INM had mixed performance relative to the market. It has outperformed in the last 3 months, returning +11.0% vs +2.7% return in SPY. But in the last 2 weeks, INM shares have been beat by the market, returning -31.5% compared to an SPY return of -2.6%.
INM support price is $.24 and resistance is $.29 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that INM stock will trade within this expected range on the day.